别名 IL-17E、IL-25、IL17E + [4] |
简介 Cytokine produced by various cells such as eosinophils, T-helper type 2 (Th2) cells or epithelial cells that plays a role in internal safety of adaptive immune responses by regulating cytokine production (PubMed:25821217, PubMed:15860795). Promotes and augments T-helper type 2 responses locally or systemically (PubMed:25821217). Exerts its activity via its receptor composed of IL17RA and IL17RB for signal transduction (By similarity). In turn, stimulates the JAK2-STAT5A pathway and promotes the secretion of type-2 associated cytokines including IL4, IL9 and IL13 (PubMed:25821217). Induces also the release of IL8, and IL6 from eosinophils through the combined activation of MAPK and NF-kappa-B pathways (PubMed:15860795). Inhibits the differentiation of T-helper (Th17) cells via the production of IL4, IL5 and IL13 (PubMed:11754819). |
靶点 |
作用机制 IL-25抑制剂 |
在研机构 |
原研机构 |
非在研适应症 |
最高研发阶段临床1/2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 IL-25抑制剂 |
在研适应症 |
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2023-12-01 |
申办/合作机构 |
开始日期2023-12-01 |
申办/合作机构 |
开始日期2023-05-08 |
申办/合作机构 |